Head and neck squamous cell carcinoma (HNSCC) is etiologically correlated with tobacco smoking and alcohol abuse, whereas a subset of oropharyngeal carcinoma is caused by infection of high risk human papillomavirus (HPV), predominantly HPV type 16 (HPV16).([@b1],[@b2]) The p53 protein, as a tumor suppressor, has a highly conserved role as a guardian of the genome and is central to cellular anticancer mechanisms.([@b3]) One of the most common molecular alterations in HNSCC is the abrogation of p53 function, which is mediated by mutations of its gene, *p53*, loss of heterozygosity of *p53*, or interaction with HPV oncoprotein E6.([@b4]--[@b6]) Tobacco smoking increases the frequency of *p53* mutations in a dose-dependent manner,([@b7]) whereas E6 binds and degrades *p53*.([@b8])

Crystal structural analyses of the effect of *p53* mutations on DNA binding classifies *p53* mutations into two distinct types, disruptive mutations and non-disruptive mutations, according to their ability to knock out *p53* function.([@b9],[@b10]) Disruptive mutations are non-conservative mutations occurring within the core DNA binding domain L2/L3, stop mutations, or frameshift mutations, and thus entirely abrogate *p53* function. All other mutations defined as non-disruptive mutations affect *p53* function in a limited fashion. It has been previously shown that HPV-positive oropharyngeal carcinoma is less likely to harbor *p53* mutations as compared with HPV-negative oropharyngeal carcinoma.([@b11]) Recently, an inverse relationship between HPV infection and disruptive mutations in oropharyngeal carcinoma has been reported, though in a small number.([@b12])

Human papillomavirus-positive oropharyngeal carcinoma is an entity clinically and epidemiologically different from HPV-negative oropharyngeal carcinoma. Oropharyngeal carcinoma that is HPV-positive has risk factors related to sexual behavior, whereas HPV-negative oropharyngeal carcinoma is linked with tobacco smoking and alcohol drinking.([@b2]) Patients with HPV-positive oropharyngeal carcinoma survive better than patients with HPV-negative oropharyngeal carcinoma.([@b13]) Of note is an increasing HPV prevalence in oropharyngeal carcinoma over time, which currently exceeds 70% in the USA and 90% in Europe.([@b14],[@b15]) However, there is a report showing the presence of a racial disparity in HPV prevalence.([@b16]) Human papillomavirus-positive tumors are significantly less frequent in black patients than in white patients. Despite these findings, the prevalence and pattern of HPV infection and *p53* mutations in HNSCC among Japanese patients remain less well established. We designed the present study to address this issue in a large patient group and to give a further insight into the association between HPV status, *p53* mutations, and clinicopathological parameters.

Materials and Methods
=====================

Patients
--------

A consecutive series of 493 patients with newly diagnosed HNSCC at Osaka University Medical School Hospital (Suita, Japan) between October 1995 and December 2012 were examined for tumor HPV status, and its subset of 283 patients were also examined for tumor *p53* mutations. All tumors were staged according to the 2002 International Union Against Cancer TNM staging system. The protocol of the present study was approved by the Institutional Review Board in December 2004, and thereafter patients provided written informed consent. The Institutional Review Board waived informed consent of patients before December 2004 due to the retrospective nature of the study, under the condition that information on the present study was disclosed on the website so that patients could apply for refusal of the enrolment.

DNA extraction
--------------

Formalin-fixed, paraffin-embedded biopsy specimens of untreated tumors were cut into 5-μm serial sections, one of which was stained with H&E, and examined using light microscopy. The other sections were used for DNA extraction by means of the DNeasy tissue kit (Qiagen, Valencia, CA, USA) when tumor cells accounted for at least 70% of the tissue sample. Tissues with \<70% tumor cells were microdissected to enrich the tumor cell content of the specimen prior to DNA extraction.

Detection and typing of high-risk HPV DNA and assessment of HPV16 physical status
---------------------------------------------------------------------------------

Human papillomavirus DNA from HPV subtypes 16, 18, 31, 33, 35, 52, or 58 was detected by PCR to amplify DNA fragments within the ORFs of *E6* and *E7* using consensus primers, pU-1M and pU-2R, as described previously.([@b17],[@b18]) The amplified products were typed by direct sequencing. Direct sequencing was carried out by the dideoxy chain termination method using the Big Dye Terminator cycle sequencing kit (Perkin-Elmer, Forester City, CA, USA). After ethanol precipitation, the samples were analyzed by the autoanalyzer (ABI PRISM 3100 genetic analyzer; Perkin-Elmer). The physical status of HPV16 was addressed according to ratio of *E2* to *E6* copy numbers, which was determined by real-time PCR amplification of the *E2* and *E6* ORFs as described previously.([@b18]) Primers for the *E2* ORF were designed to amplify the *E2* hinge region, which is usually deleted after viral integration into the host genome.([@b19]) The *E2* and *E6* ORFs were quantified with the ABI PRISM 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). CaSki cells, containing 500 integrated copies of HPV16 DNA per cell, were used as a positive control.([@b20])

Detection of *p53* gene mutations
---------------------------------

Polymerase chain reaction amplification followed by SSCP analysis and direct sequencing was carried out as previously described([@b21]) to detect *p53* mutations in exons 4--8, containing 94% of all mutations described in HNSCC (International Agency for Research on Cancer TP53 Database, <http://p53.iarc.fr/>). The PCR primer pairs for the amplification are described elsewhere.([@b22]) The SSCP bands that showed altered mobility as compared to a wild-type control (human lymphocyte DNA), were extracted from the gel and reamplified by PCR to enrich mutated alleles. The mutated alleles were purified using the QIAquick PCR purification kit (Qiagen). Direct sequencing was carried out as described above.

Statistical analysis
--------------------

Associations between HPV infection, *p53* mutations, and a disruptive mutation with clinicopathological parameters were assessed by univariate analyses involving logistic regression model or Clopper--Pearson\'s exact test, as appropriate. Multivariate analyses were made by forward stepwise logistic regression model. Akaike\'s information criterion([@b23]) was used to evaluate the relative usefulness of the model. Differences in HPV prevalence, *p53* mutation prevalence, and pattern of *p53* mutations between groups were examined by Fisher\'s exact test. Trend in HPV prevalence over calendar time was evaluated by the Cochran--Armitage test. All statistical tests were two-tailed at a significant level of 0.05. All data were analyzed using [sas]{.smallcaps} Version 9.3 (SAS Institute, Cary, NC, USA).

Patients were classified as light and heavy smokers if their lifetime cigarette exposure was below and equal to or above the median pack-years in each analyzed group, respectively. Alcohol abuse was estimated by alcohol index, which was calculated by the formula: number of alcoholic units per day multiplied by year-duration. Twenty-eight grams of alcohol contained in alcoholic beverages corresponded to one unit of alcohol. Patients were classified as light and heavy drinkers if their lifetime alcohol consumption was below and equal to or above the median alcohol index in each analyzed group, respectively. Ever smokers and drinkers were defined as former plus current smokers and drinkers, respectively.

Results
=======

Prevalence and pattern of HPV in HNSCCs
---------------------------------------

There was a striking difference in HPV prevalence between oropharyngeal carcinoma and non-oropharyngeal carcinoma (Table [1](#tbl1){ref-type="table"}). Fifty-six of 163 (34.4%) oropharyngeal carcinomas were HPV-positive, whereas 12 of 330 (3.6%) non-oropharyngeal carcinomas were HPV-positive (*P* \< 0.001). Prevalence of HPV in oral, hypopharyngeal, and laryngeal carcinomas was drastically decreased compared with that in oropharyngeal carcinoma (*P* \< 0.001). Of note is nasopharyngeal carcinoma, 12.0% of which was HPV-positive, although the prevalence was still significantly less than in oropharyngeal carcinoma (odds ratio (OR), 0.3; 95% confidence interval (CI), 0.05--0.9; *P* = 0.04). As summarized in Table [2](#tbl2){ref-type="table"}, HPV16 was the most prevalent, accounting for 62 of 68 (91.1%) HPV-positive tumors. All HPV-positive tumors were positive for a single type of high-risk HPV. An *E2* to *E6* transcript ratio consistent with complete viral integration was detected in 24 of 62 (38.7%) HPV16-positive tumors. The remaining 38 (61.3%) HPV16-positive tumors showed the presence of both episomal and integrated viral forms.

###### 

Prevalence of human papillomavirus (HPV) in head and neck squamous cell carcinomas according to primary tumor site (*n* = 493)

  Primary site             Total no.   HPV-positive *n* (%)   Odds ratio[†](#tf1-1){ref-type="table-fn"}   95% CI           *P*-value
  ------------------------ ----------- ---------------------- -------------------------------------------- ---------------- -----------
  Oropharynx               163         56 (34.4)              Reference                                                     
  Non-oropharynx (whole)   330         12 (3.6)               0.1                                          0.0400--0.1000   \<0.001
  Oral cavity              57          0 (0.0)                0.0                                          0.0008--0.2000   \<0.001
  Nasopharynx              25          3 (12.0)               0.3                                          0.0500--0.9000   0.035
  Hypopharynx              171         6 (3.5)                0.1                                          0.0200--0.2000   \<0.001
  Larynx                   77          3 (3.9)                0.1                                          0.0200--0.3000   \<0.001

Univariate analysis was made by logistic regression model, except for oral cavity that was made by the Clopper--Pearson method. CI, confidence interval.

###### 

Subtype of human papillomavirus (HPV) and physical status of HPV16 (*n* = 68)

  Type of HPV   No.   \%     Physical status               
  ------------- ----- ------ ----------------- ----------- ---------
  HPV16         62    91.1   24 (38.7)         38 (61.3)   0 (0.0)
  HPV18         1     1.5                                  
  HPV33         1     1.5                                  
  HPV35         3     4.4                                  
  HPV58         1     1.5                                  

Association of HPV status with clinicopathological factors in oropharyngeal carcinoma
-------------------------------------------------------------------------------------

As HPV-positive tumors were highly predominant in oropharyngeal carcinoma, we addressed the relationship between HPV status and clinicopathological factors in the single group of patients with oropharyngeal carcinoma (Table [3](#tbl3){ref-type="table"}). Older patients, heavy smokers, and heavy drinkers were less likely to have HPV-positive tumors than younger patients (OR, 0.4; 95% CI, 0.2--0.8; *P* = 0.009), light smokers (OR, 0.4; 95% CI, 0.2--0.7; *P* = 0.003), and light drinkers (OR, 0.3; 95% CI, 0.1--0.6; *P* \< 0.001), respectively. The prevalence of HPV infection was significantly decreased in the posterior wall and soft palate (OR, 0.1; 95% CI, 0.02--0.4; *P* \< 0.001) as compared with the palatine tonsil. In contrast, poorly differentiated or undifferentiated tumors were more likely to be HPV-positive than well differentiated tumors (OR, 3.7; 95% CI, 1.3--11.0; *P* = 0.01). In the multivariate analysis, age, alcohol drinking, and subsite remained as significant determinants of HPV infection.

###### 

Association of human papillomavirus (HPV) status with clinicopathological factors in oropharyngeal carcinoma (*n* = 163)

  Factor and level                                                                     Total no.   HPV-positive   Univariate analysis[†](#tf3-1){ref-type="table-fn"}   Multivariate analysis[†](#tf3-1){ref-type="table-fn"}                                     
  ------------------------------------------------------------------------------------ ----------- -------------- ----------------------------------------------------- ------------------------------------------------------- --------- ----------- ----------- ---------
  Sex                                                                                                                                                                                                                                                             
   Male                                                                                140         46 (32.9)      Reference                                                                                                                                       
   Female                                                                              23          10 (43.5)      1.6                                                   0.6--3.8                                                0.327                             
  Age at diagnosis[‡](#tf3-2){ref-type="table-fn"}                                                                                                                                                                                                                
   \<65 years                                                                          73          33 (45.2)      Reference                                                                                                               Reference               
   ≥65 years                                                                           90          23 (25.6)      0.4                                                   0.2--0.8                                                0.009     0.4         0.2--0.7    0.005
   Per 10 years                                                                                                   0.7                                                   0.5--1.0                                                0.030                             
  Cigarrete smoking[‡](#tf3-2){ref-type="table-fn"},[§](#tf3-3){ref-type="table-fn"}                                                                                                                                                                              
   \<42 pack-years                                                                     81          37 (45.7)      Reference                                                                                                                                       
   ≥42 pack years                                                                      81          19 (23.5)      0.4                                                   0.2--0.7                                                0.003                             
   Per 5 pack-years                                                                                               0.9                                                   0.8--1.0                                                \<0.001                           
   Never                                                                               22          13 (59.1)      Reference                                                                                                                                       
   Ever                                                                                140         43 (30.7)      0.3                                                   0.1--0.8                                                0.011                             
  Alcohol drinking[‡](#tf3-2){ref-type="table-fn"},[§](#tf3-3){ref-type="table-fn"}                                                                                                                                                                               
   \<69 units of sake index                                                            81          39 (48.2)      Reference                                                                                                               Reference               
   ≥69 units of sake index                                                             81          17 (21.0)      0.3                                                   0.1--0.6                                                \<0.001   0.3         0.1--0.6    0.001
   Per 5 units of sake index                                                                                      0.9                                                   0.9--1.0                                                \<0.001                           
   Never                                                                               37          20 (54.1)      Reference                                                                                                                                       
   Ever                                                                                125         36 (28.8)      0.3                                                   0.2--0.7                                                0.005                             
  Subsite                                                                                                                                                                                                                                                         
   Palatine tonsil                                                                     93          42 (45.2)      Reference                                                                                                               Reference               
   Lingual tonsil                                                                      43          12 (27.9)      0.5                                                   0.2--1.0                                                0.053     0.4         0.2--0.9    0.040
   Posterior wall and soft palate                                                      27          2 (7.4)        0.1                                                   0.02--0.4                                               \<0.001   0.1         0.02--0.4   \<0.001
  Tumor stage                                                                                                                                                                                                                                                     
   T1--T2                                                                              96          36 (37.5)      Reference                                                                                                                                       
   T3--T4                                                                              67          20 (29.9)      0.7                                                   0.4--1.4                                                0.310                             
  Nodal stage                                                                                                                                                                                                                                                     
   N0--N1                                                                              59          17 (28.8)      Reference                                                                                                                                       
   N2--N3                                                                              104         39 (37.5)      1.5                                                   0.8--3.0                                                0.300                             
  Cell differentiation                                                                                                                                                                                                                                            
   Well                                                                                34          7 (20.6)       Reference                                                                                                                                       
   Moderate                                                                            72          23 (31.9)      1.8                                                   0.7--5.1                                                0.214                             
   Poor--undifferentiated                                                              39          19 (48.7)      3.7                                                   1.3--11.0                                               0.011                             
   Unknown                                                                             18          7 (38.9)       2.5                                                   0.7--8.9                                                0.163                             

Univariate analysis was carried out using the logistic regression model; multivariate analysis was by the forward stepwise logistic regression model.

Median of age at diagnosis, cigarette smoking, and alcohol abuse was 65 year, 42 pack-years, and 69 units of sake index, respectively.

One pack-year and one unit of sake index are defined as the equivalent of smoking one pack of cigarettes per day for 1 year and drinking 28 g alcohol per day for 1 year, respectively. CI, confidence interval.

Trend of HPV prevalence in oropharyngeal carcinoma
--------------------------------------------------

As HPV-positive tumors were specific to the palatine and lingual tonsils among subsites of the oropharynx, we addressed the chronological change of HPV prevalence in oropharyngeal carcinoma originating from these subsites. Prevalence of HPV was increased from 36.8% during 1995 to 1999, 39.0% during 2000 to 2009, to 48.3% during 2010 to 2012 (Fig. [1](#fig01){ref-type="fig"}). This increasing trend across calendar periods was statistically significant (*P* \< 0.001).

![Prevalence of human papillomavirus infection in carcinomas of the palatine and lingual tonsils across three calendar periods (1995--1999, 2000--2009, and 2010--2012). An increasing trend was statistically significant (*P* \< 0.001). The number of specimens evaluable for each assay is shown below the *x*-axis.](cas0105-0409-f1){#fig01}

Association of HPV status with *p53* mutations
----------------------------------------------

In oropharyngeal carcinoma, 28 of 57 (49.1%) tumors carrying wild-type *p53* were HPV-positive, whereas 2 of 25 (8.0%) tumors harboring any *p53* mutation and none of 10 tumors harboring a disruptive mutation were HPV-positive (Table [4](#tbl4){ref-type="table"}). In turn, 2 of 30 (6.7%) HPV-positive tumors harbored *p53* mutations. Accordingly, tumors harboring any *p53* mutation, and particularly a disruptive mutation, were less likely to be HPV-positive as compared with tumors carrying wild-type *p53* (for any *p53* mutation: OR, 0.09; 95% CI, 0.01--0.3; *P* \< 0.001; for a disruptive mutation: OR, 0.05; 95% CI, 0.003--0.9; *P* \< 0.001), indicating an inverse relationship between HPV infection and any *p53* mutation and a disruptive mutation. After adjustment for tobacco smoking and alcohol drinking in the multivariate analysis, *p53* mutations remained inversely associated with HPV infection (*P* = 0.005). As none of the tumors harboring a disruptive mutation was HPV-positive, multivariate analysis of a disruptive mutation at a risk of HPV infection was prohibited. We also examined whether there was an inverse relationship between HPV infection and *p53* mutations in non-oropharyngeal carcinoma as observed in oropharyngeal carcinoma. As shown in Table [5](#tbl5){ref-type="table"} of 117 (4.3%) tumors carrying wild-type *p53* and 4 of 84 (4.8%) tumors harboring any *p53* mutation were HPV-positive, indicating the absence of the inverse relationship. Of note, all the mutations observed in HPV-positive tumors were non-disruptive. Human papillomavirus infection and *p53* disruptive mutation did not coexist even in non-oropharyngeal carcinoma.

###### 

Relationship between human papillomavirus (HPV) status and *p53* mutations in head and neck squamous cell carcinomas (*n* = 283)

                                *p53* mutations   Total no.   HPV-positive   Univariate analysis[†](#tf4-1){ref-type="table-fn"}   Multivariate analysis[‡](#tf4-2){ref-type="table-fn"},[§](#tf4-3){ref-type="table-fn"}                                    
  ----------------------------- ----------------- ----------- -------------- ----------------------------------------------------- ---------------------------------------------------------------------------------------- ----- ----------- ----------- -- --
  Oropharyngeal carcinoma       *p53* status      Wild-type   57             28 (49.1)                                             Reference                                                                                                  Reference      
  Mutant                        25                2 (8.0)     0.09           0.01--0.3                                             \<0.001                                                                                  0.1   0.02--0.5   0.005          
  Mutation category             Wild-type         57          28 (49.1)      Reference                                                                                                                                                                       
  Non-disruptive                15                2 (13.3)    0.2            0.02--0.6                                             0.008                                                                                                                     
  Disruptive                    10                0 (0.0)     0.05           0.003--0.9                                            \<0.001                                                                                                                   
  Non-oropharyngeal carcinoma   *p53* status      Wild-type   117            5 (4.3)                                               Reference                                                                                                                 
  Mutant                        84                4 (4.8)     1.1            0.3--4.4                                              0.868                                                                                                                     
  Mutation category             Wild-type         117         5 (4.3)        Reference                                                                                                                                                                       
  Non-disruptive                61                4 (6.6)     1.6            0.4--6.2                                              0.516                                                                                                                     
  Disruptive                    23                0 (0.0)     0.4            0.02--7.4                                             0.176                                                                                                                     

Univariate analysis was carried out using the logistic regression model for *p53* status and by the Clopper--Pearson method for mutation category.

Multivariate analysis was carried out using the forward stepwise logistic regression model.

Ajusted for cigarette smoking and alcohol drinking. CI, confidence interval.

###### 

Association between *p53* mutations and clinicopathological factors in Japanese patients with head and neck squamous cell carcinoma (*n* = 283)

  Factor and level                                                                     Total no.   *p53* status   Mutation category                                                               
  ------------------------------------------------------------------------------------ ----------- -------------- ------------------- ------------ --------- ----------- ----------- ------------ -------
  Sex                                                                                                                                                                                             
   Male                                                                                240         94 (39.2)      Reference                                  31 (33.0)   Reference                
   Female                                                                              43          15 (34.9)      0.8                 0.4--1.6     0.593     2 (13.3)    0.3         0.05--1.2    0.101
  Age at diagnosis[‡](#tf5-2){ref-type="table-fn"}                                                                                                                                                
   \<63 years                                                                          131         45 (34.4)      Reference                                  19 (42.2)   Reference                
   ≥63 years                                                                           152         64 (42.1)      1.4                 0.9--2.3     0.181     14 (21.9)   0.4         0.2--0.9     0.023
   Per 10 years                                                                                                   1.2                 0.9--1.5     0.140                 0.7         0.5--1.1     0.120
  Cigarrete smoking[‡](#tf5-2){ref-type="table-fn"},[§](#tf5-3){ref-type="table-fn"}                                                                                                              
   \<45 pack-years                                                                     131         43 (32.8)      Reference                                  11 (25.6)   Reference                
   ≥45 pack years                                                                      146         64 (43.8)      1.6                 1.0--2.6     0.060     21 (32.8)   1.4         0.6--3.4     0.421
   Unknown                                                                             6           2 (33.3)       1.0                 0.2--5.8     0.979     1 (50.0)    2.9         0.1--77.8    0.472
   Per 5 pack-years                                                                                               1.0                 1.0--1.1     0.040                 1.0         1.0--1.1     0.310
   Never                                                                               47          15 (31.9)      Reference                                  1 (6.7)     Reference                
   Ever                                                                                230         92 (40.0)      1.4                 0.7--2.8     0.295     31 (33.7)   7.1         1.3--131.8   0.017
  Alcohol drinking[†](#tf5-1){ref-type="table-fn"},[§](#tf5-3){ref-type="table-fn"}                                                                                                               
   \<80 units of sake index                                                            135         41 (30.4)      Reference                                  13 (31.7)   Reference                
   ≥80 units of sake index                                                             142         66 (46.5)      2.0                 1.2--3.3     0.006     19 (28.8)   0.9         0.4--2.1     0.749
   Unknown                                                                             6           2 (33.3)       1.1                 0.2--6.1     0.878     1 (50.0)    2.2         0.08--57.4   0.601
   Per 5 units of sake index                                                                                      1.0                 1.0--1.0     0.210                 1.0         1.0--1.0     0.240
   Never                                                                               59          14 (23.7)      Reference                                  3 (21.4)    Reference                
   Ever                                                                                218         93 (42.7)      2.4                 1.3--4.8     0.007     29 (31.2)   1.7         0.5--7.7     0.445
  Primary site                                                                                                                                                                                    
   Oral cavity                                                                         37          18 (48.7)      Reference                                  2 (11.1)    Reference                
   Nasopharynx                                                                         21          1 (4.8)        0.1                 0.003--0.3   \<0.001   0 (0.0)     2.2         0.1--70.4    0.632
   HPV-negative ooropharynx                                                            52          23 (44.2)      0.8                 0.4--2.0     0.680     10 (43.5)   6.2         1.3--44.9    0.019
   HPV-positive oropharynx                                                             30          2 (6.7)        0.1                 0.01--0.3    \<0.001   0 (0.0)     1.3         0.05--36.3   0.505
   Hypopharynx                                                                         108         49 (45.4)      0.9                 0.4--1.9     0.730     18 (36.7)   4.6         1.1--31.5    0.030
   Larynx                                                                              35          16 (45.7)      0.9                 0.3--2.2     0.803     3 (18.8)    1.8         0.3--15.7    0.526
  Tumor stage                                                                                                                                                                                     
   T1--T2                                                                              138         55 (39.9)      Reference                                  15 (27.3)   Reference                
   T3--T4                                                                              145         54 (37.2)      0.9                 0.6--1.4     0.652     18 (33.3)   1.3         0.6--3.1     0.491
  Nodal stage                                                                                                                                                                                     
   N0--N1                                                                              132         51 (38.6)      Reference                                  12 (23.5)   Reference                
   N2--N3                                                                              151         58 (38.4)      1.0                 0.6--1.6     0.969     21 (36.2)   1.8         0.8--4.4     0.148
  Cell differentiation                                                                                                                                                                            
   Well                                                                                79          37 (46.8)      Reference                                  12 (32.4)   Reference                
   Moderate                                                                            119         50 (42.0)      0.8                 0.5--1.5     0.504     16 (32.0)   1.0         0.4--2.5     0.966
   Poor--undifferentiated                                                              69          19 (27.5)      0.4                 0.2--0.9     0.015     4 (21.1)    0.6         0.1--1.9     0.364
   Unknown                                                                             16          3 (18.8)       0.3                 0.1--0.9     0.031     1           1.0         0.05--11.9   0.975
  HPV status                                                                                                                                                                                      
   Negative                                                                            244         103 (42.2)     Reference                                  33 (32.0)   Reference                
   Positive                                                                            39          6 (15.4)       0.2                 0.09--0.6    \<0.001   0 (0.0)     0.2         0.009--0.8   0.034

Univariate analysis was carried out using the logistic regression model.

Median of age at diagnosis, cigarette smoking, and alcohol abuse was 63 years, 45 pack-years, and 80 units of sake index, respectively.

One pack-year and one unit of sake index are defined as the equivalent of smoking one pack of cigarettes per day for 1 year and drinking 28 g alcohol per day for 1 year, respectively. CI, confidence interval; HPV, human papillomavirus.

Prevalence and pattern of *p53* mutations in HNSCCs
---------------------------------------------------

One hundred and nine of 283 (38.5%) tumors were found to harbor *p53* mutations. Of 109 tumors with *p53* mutations, 76 (69.7%) and 33 (30.3%) were classified to harbor a non-disruptive mutation and a disruptive mutation, respectively. Table [5](#tbl5){ref-type="table"} summarizes the prevalence of any *p53* mutation and a disruptive mutation in relation to clinicopathological factors and HPV status. Tumors in heavy smokers and heavy drinkers were more likely to harbor *p53* mutations than tumors in light smokers (OR, 1.6; 95% CI, 1.0--2.6; *P* = 0.06) and light drinkers (OR, 2.0; 95% CI, 1.2--3.3; *P* = 0.006), respectively. Although the difference between light and heavy smokers was marginal, there was an increasing trend of *p53* mutations in proportion to the amount of tobacco smoking (OR, 1.0; 95% CI, 1.0--1.1; *P* = 0.04, per 5 pack-years). Of note is a striking difference between virus-unrelated HNSCCs and virus-related HNSCCs. Human papillomavirus-positive oropharyngeal carcinoma and nasopharyngeal carcinoma that is caused by Epstein--Barr virus([@b24]) constitute virus-related HNSCCs. Only one of 21 (4.8%) nasopharyngeal carcinomas and 2 of 30 (6.7%) HPV-positive oropharyngeal carcinomas harbored *p53* mutations. In contrast, the frequency of *p*53 mutations ranged from 44.2% to 48.7% in virus-unrelated HNSCCs. The frequency of any *p53* mutation was significantly higher in virus-unrelated HNSCCs than in virus-related HNSCCs (45.7% *vs* 5.9%, *P* \< 0.001). Compared with oral carcinoma, nasopharyngeal and HPV-positive oropharyngeal carcinomas showed a significantly lower prevalence of *p53* mutations (for nasopharyngeal carcinoma: OR, 0.1; 95% CI, 0.003--0.3; *P* \< 0.001; for HPV-positive oropharyngeal carcinoma: OR, 0.1; 95% CI, 0.01--0.3; *P* \< 0.001). Moreover, as in HPV-positive oropharyngeal carcinoma, no disruptive mutation was found in nasopharyngeal carcinoma.

Association of *p53* mutations with clinicopathological parameters in virus-unrelated HNSCCs
--------------------------------------------------------------------------------------------

As *p53* mutations were extremely uncommon in virus-related HNSCCs, we sought to address an association of *p53* mutations and a disruptive mutation with clinicopathological parameters in virus-unrelated HNSCCs (Table [6](#tbl6){ref-type="table"}). Association of *p53* mutations with tobacco smoking and alcohol drinking, which was evident in the whole study group, disappeared in the subpopulation of virus-unrelated HNSCCs. No clinicopathological parameter was associated with *p53* mutations, whereas a disruptive mutation significantly correlated with tobacco exposure and primary site. The proportion of tumors with a disruptive mutation in tumors with any mutation was more frequent in ever-smoker patients than in never-smoker patients (7.1% *vs* 34.1%; OR, 6.7; 95% CI, 1.2--124.8; *P* = 0.02). As compared with oral carcinoma, HPV-negative oropharyngeal carcinoma and hypopharyngeal carcinoma were more likely to harbor a disruptive mutation (for HPV-negative oropharyngeal carcinoma: OR, 6.2; 95% CI, 1.3--44.9; *P* = 0.02; for hypopharyngeal carcinoma: OR, 4.6; 95% CI, 1.1--31.5; *P* = 0.03). After adjustment for age and tobacco exposure, HPV-negative oropharyngeal carcinoma and hypopharyngeal carcinoma remained independently associated with a disruptive mutation compared with oral carcinoma (for HPV-negative oropharyngeal carcinoma: OR, 7.6; 95% CI, 1.5--60.0; *P* = 0.01; for hypopharyngeal carcinoma: OR 4.9; 95% CI, 1.1--34.7; *P* = 0.03). Tobacco exposure also independently correlated with a disruptive mutation after adjustment for age and primary site (OR, 6.0; 95% CI, 1.0--115.3; *P* = 0.04).

###### 

Association between *p53* mutations and clinicopathological factors in virus-unrelated head and neck squamous cell carcinomas (*n* = 232)

  Factor and level                                                                     *p53* status   Mutation category                                                                                                          
  ------------------------------------------------------------------------------------ -------------- ------------------- ----------- ------------ ------- ----------- ----------- ------------ ------- ----------- ------------ -------
  Sex                                                                                                                                                                                                                            
   Male                                                                                202            93 (46.0)           Reference                        31 (33.3)   Reference                                                 
   Female                                                                              30             13 (43.3)           0.9         0.4--1.9     0.781   2 (15.4)    0.4         0.05--1.5    0.166                            
  Age at diagnosis[‡](#tf6-2){ref-type="table-fn"}                                                                                                                                                                               
   \<63 years                                                                          102            45 (44.1)           Reference                        19 (42.2)   Reference                        Reference                
   ≥63 years                                                                           130            61 (46.9)           1.1         0.7--1.9     0.670   14 (23.0)   0.4         0.2--0.9     0.035   0.4         0.1--1.0     0.042
   per 10 years                                                                                                           1.1         0.8--1.4     0.710               0.7         0.5--1.2     0.180                            
  Cigarrete smoking[‡](#tf6-2){ref-type="table-fn"},[§](#tf6-3){ref-type="table-fn"}                                                                                                                                             
   \<45 pack-years                                                                     95             42 (44.2)           Reference                        11 (26.2)   Reference                                                 
   ≥45 pack years                                                                      135            63 (46.7)           1.1         0.7--1.9     0.713   21 (33.3)   1.4         0.6--3.4     0.434                            
   Unknown                                                                             2              1 (50.0)            1.3         0.08--22.2   0.831   1 (100.0)                                                             
   Per 5 pack-years                                                                                                       1.0         1.0--1.0     0.670               1.0         1.0--1.1     0.340                            
   Never                                                                               31             14 (45.2)           Reference                        1 (7.1)     Reference                        Reference                
   Ever                                                                                199            91 (45.7)           1.0         0.5--2.2     0.953   31 (34.1)   6.7         1.2--124.8   0.023   6.0         1.0--115.3   0.045
  Alcohol drinking[‡](#tf6-2){ref-type="table-fn"},[§](#tf6-3){ref-type="table-fn"}                                                                                                                                              
   \<80 units of sake index                                                            97             40 (41.2)           Reference                        13 (32.5)   Reference                                                 
   ≥80 units of sake index                                                             133            65 (48.9)           1.4         0.8--2.3     0.250   19 (29.2)   0.9         0.4--2.0     0.724                            
   Unknown                                                                             2              1 (50.0)            1.4         0.08--1.4    0.830   1 (100.0)                                                             
   Per 5 units of sake index                                                                                              1.0         1.0--1.0     0.740               1.0         1.0--1.0     0.260                            
   Never                                                                               36             13 (36.1)           Reference                        3 (23.1)    Reference                                                 
   Ever                                                                                194            92 (47.4)           1.6         0.8--3.4     0.207   29 (31.5)   1.5         0.4--7.2     0.527                            
  Primary site                                                                                                                                                                                                                   
   Oral cavity                                                                         37             18 (48.7)           Reference                        2 (11.1)    Reference                        Reference                
   HPV-negative oropharynx                                                             52             23 (44.2)           0.8         0.4--2.0     0.680   10 (43.5)   6.2         1.3--44.9    0.019   7.6         1.5--60.0    0.014
   Hypopharynx                                                                         108            49 (45.4)           0.9         0.4--1.9     0.730   18 (36.7)   4.6         1.1--31.5    0.030   4.9         1.1--34.7    0.033
   Larynx                                                                              35             16 (45.7)           0.9         0.3--2.2     0.803   3 (18.8)    1.8         0.3--15.7    0.530   1.4         0.1--14.1    0.763
  Tumor stage                                                                                                                                                                                                                    
   T1--T2                                                                              107            54 (50.5)           Reference                        15 (27.8)   Reference                                                 
   T3--T4                                                                              125            52 (41.6)           0.7         0.4--1.2     0.175   18 (34.6)   1.4         0.6--3.2     0.447                            
  Nodal stage                                                                                                                                                                                                                    
   N0--N1                                                                              106            50 (47.2)           Reference                        12 (24.0)   Reference                                                 
   N2--N3                                                                              126            56 (44.4)           0.9         0.5--1.5     0.678   21 (37.5)   1.9         0.8--4.5     0.132                            
  Cell differentiation                                                                                                                                                                                                           
   Well                                                                                73             37 (50.7)           Reference                        12 (32.4)   Reference                                                 
   Moderate                                                                            106            49 (46.2)           0.8         0.5--1.5     0.557   16 (32.7)   1.0         0.4--2.5     0.981                            
   Poor--undifferntiated                                                               41             17 (41.5)           0.7         0.3--1.5     0.343   4 (23.5)    0.6         0.2--2.3     0.500                            
   Unknown                                                                             12             3 (25.0)            0.3         0.07--1.2    0.091   1 (33.3)    1.0         0.05--11.9   0.975                            

Univariate analysis was carried out using the logistic regression model; multivariate analysis was carried out using the forward stepwise logistic regression model.

Median of age at diagnosis, cigarette smoking, and alcohol abuse was 64 years, 49 pack-years, and 100 units of sake index, respectively.

One pack-year and one unit of sake index are defined as the equivalent of smoking one pack of cigarettes per day for 1 year and drinking 28 g alcohol per day for 1 year, respectively. CI, confidence interval.

Pattern of *p53* mutations in virus-unrelated HNSCCs
----------------------------------------------------

The prevalence of any *p53* mutation was not associated with tobacco smoking in virus-unrelated HNSCCs, as shown in Table [6](#tbl6){ref-type="table"}, whereas tobacco carcinogen is known to link with a specific type of mutagenesis.([@b25]) We addressed the pattern of *p53* mutations in virus-unrelated HNSCCs, in relation to tobacco exposure. One hundred and twelve of 232 (48.3%) tumors harbored a total of 165 *p53* mutations (22 tumors with two distinct mutations, 6 with three, 2 with four, 2 with five, and 1 with six), including 118 missense mutations, 12 nonsense mutations, 8 frame-shifts, and 27 silent mutations (detail of the mutations in [Table S1](#SD1){ref-type="supplementary-material"}), although six tumors harbored only silent mutations. The codon distribution of *p53* mutations differed depending on tobacco exposure. In ever-smokers, 19 of 143 (13.2%) mutations were detected at codons described as "hotspots" for transversions (codon 157, one mutation; codon 158, six mutations; codon 245, six mutations; codon 248, five mutations; codon 273, one mutation),([@b26]) whereas, in never-smokers, mutations at hotspots were found only at codon 245, accounting for 2 of 22 (9.1%) mutations. Figure [2](#fig02){ref-type="fig"} shows the types of mutations according to smoking status. Transversions accounted for 39.2% of mutations in ever-smokers, whereas the vast majority (81.8%) of mutations in never-smokers were transitions. Two types of mutations showed consistent difference in relation to smoking. G:C to T:A transversions were more prevalent in ever-smokers than in never-smokers (22.4% *vs* 4.5%, *P* = 0.04), whereas G:C to A:T transitions at CpG sites were less prevalent in ever-smokers than in never-smokers (10.5% *vs* 27.3%, *P* = 0.04).

![Pattern of *p53* mutations in human papillomavirus-unrelated head and neck tumors from never- and ever-smokers. One hundred sixty-five mutations are represented in 112 patients. Never-smokers showed a higher prevalence of G:C to A:T transitions at CpG sites than ever-smokers (\**P* = 0.04). Ever-smokers showed a higher prevalence of G:C to T:A transversions than never-smokers (\*\**P* = 0.04). Others represent insertion and deletion.](cas0105-0409-f2){#fig02}

Discussion
==========

In the present study we established the prevalence and pattern of HPV in Japanese patients with HNSCC. The most prevalent oropharyngeal carcinoma tumors were HPV-positive, especially those arising in the palatine and lingual tonsils, where HPV-positive tumors accounted for 45.2% and 27.9%, respectively, although this prevalence is still lower than in North America and Europe.([@b14],[@b15]) In the USA, HPV prevalence in oropharyngeal carcinoma significantly increased over calendar time, reaching up to 72% during 2000 to 2004.([@b14]) We also showed the increasing trend in Japan. However, there is a racial disparity in HPV prevalence.([@b16]) The prevalence is significantly lower in black patients than in white patients. Sexual behavior, which is significantly associated with the pathogenesis of HPV-positive oropharyngeal carcinoma,([@b2],[@b26]) might differ among races or nations. Additionally, the rate of smoking, which is the other major cause of oropharyngeal carcinogenesis, is higher in Japan than in the USA.([@b27]) Given this knowledge, it remains uncertain whether HPV prevalence in oropharyngeal carcinoma among Japanese will reach as high as that among white populations. As for HPV subtypes, HPV16 commanded a vast majority (91.1%) of HPV-positive tumors in Japan, which is consistent with a worldwide systematic review.([@b28])

We addressed factors associated with HPV infection in oropharyngeal carcinoma. In accordance with previous reports,([@b11],[@b29]) we found that tobacco smoking, alcohol drinking, and older age were inversely related with HPV infection. Likewise, HPV-positive tumors were predominant in the palatine and lingual tonsils, and differentiation grade of HPV-positive tumors was poor. Although HPV-positive tumors present mostly at an early tumor stage and advanced nodal stage,([@b15]) we failed to show such findings, the reason for which remains unknown. An additional discordance from previous reports was the absence of a gender gap. We did not find a higher rate of HPV-positive tumors in men than in women. The higher rate in men in North America and Europe is considered to be attributed to HPV prevalence in cervical rather than penile tissue, which might facilitate the chance of HPV infection when performing oral sex on a woman. Differences in oral sex behavior might be responsible for the absence of a gender gap in Japan.

Gillison *et al*.([@b11]) examined HPV status and *p53* mutations in 34 oropharyngeal carcinomas, and showed that HPV-positive tumors as compared with HPV-negative tumors were less likely to harbor *p53* mutations. Westra *et al*.([@b12]) showed that 12 of 20 (60.0%) tonsillar carcinomas without a disruptive mutation were HPV-positive, whereas none of 7 tonsillar carcinomas carrying a disruptive mutation was HPV-positive. In the present study we further verified these findings in a larger scale, and established the inverse relationship between HPV infection and any *p53* mutation or a disruptive mutation in oropharyngeal carcinoma. However, we found the absence of that inverse relationship in non-oropharyngeal HNSCCs, as previously reported.([@b11]) This finding, given the report that *p53* mutations of HNSCCs are associated with poor outcome,([@b30]) might partially explain why a prognostic advantage of HPV-positive tumors disappear in non-oropharyngeal HNSCCs.([@b31]) We also found that HPV infection and a disruptive mutation did not coexist, irrespective of primary tumor site, indicating that the coexistence of HPV infection and *p53* mutations occurs only when the mutations are non-disruptive. Disruptive mutations are selectively associated with allelic loss of wild-type *p53*,([@b32]) and confer "gain of function" phenotype.([@b33],[@b34]) It seems likely that disruptive mutations lead directly to the acquisition of malignant phenotype, whereas non-disruptive mutations, in concert with other events targeting the *p53* pathway such as transcriptionally active HPV, might produce a synergistic effect of *p53* functional abrogation.

Of interest is the finding that, although there was a positive association between *p53* mutations and tobacco smoking in the whole patient group, this association disappeared in the subpopulation of virus-unrelated HNSCCs. This is most probably because as high as 76.6% of virus-related HNSCC patients with known history of tobacco smoking were light or never-smokers (data not shown), and because no \<94.1% of virus-related HNSCCs carried wild-type *p53* (Table [5](#tbl5){ref-type="table"}). There has been a series of studies showing that the frequency of *p53* mutations in HNSCCs increases in proportion to the level of exposure to tobacco smoking.([@b35]--[@b37]) In these studies, oropharyngeal carcinoma accounted for a substantial portion of the analyzed population, and HPV status of oropharyngeal carcinoma was unknown in spite of the inverse relationship of HPV infection with *p53* mutations and tobacco smoking.([@b35]--[@b37]) This background behind the studies might explain, at least in part, the divergence from our finding. Of note, in virus-unrelated HNSCCs a disruptive mutation was independently associated with primary site (the oropharynx and hypopharynx). This finding is potentially interesting because hypopharyngeal carcinoma is the most fatal among HNSCCs,([@b29]) and because *p53* disruptive mutations serve as an adverse prognostic factor in HNSCCs.([@b29]) Another interesting finding is that in virus-unrelated HNSCCs, smoking was associated with increased prevalence of G:C to T:A transversions as reported for carcinomas of the lung([@b38]) and upper aerodigestive tract.([@b35]) This type of mutagenesis is caused by bulky carcinogen from tobacco smoke, such as polycyclic aromatic hydrocarbons.([@b25]) Conversely, we found that smoking was associated with decreased prevalence of G:C to A:T transitions at CpG sites, a type of mutation commonly associated with endogenous mutagenesis processes, such as spontaneous deamination of methylated cytosine into thymine. This phenomenon has also been described in carcinomas of the upper aerodigestive tract.([@b35])

In conclusion, HNSCC is etiologically classified into virus-related and virus-unrelated subgroups. In virus-related HNSCC, *p53* mutations are uncommon with the absence of a disruptive mutation. In virus-unrelated HNSCC, although *p53* mutations are common, the prevalence is not associated with tobacco and alcohol exposure. Disruptive mutagenesis of *p53* is closely related with primary site.
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**Table S1** Details of *p53* mutations in virus-unrelated head and neck squamous cell carcinomas.
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